Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Foamix Pharma Ord (NQ: FOMX )

2.990 USD UNCHANGED
Last Price Updated: 6:50 PM EST, Mar 6, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.990
Bid (Size) 2.950 (1)
Ask (Size) 3.000 (8)
Prev. Close 2.990
Today's Range 2.990 - 2.990
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company") announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix") following the satisfaction of... 
From PR Newswire
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
From GlobeNewswire News Releases

Performance

More News

Read More
Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference
From GlobeNewswire News Releases
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
From PR Newswire
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
From GlobeNewswire News Releases
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
From GlobeNewswire News Releases
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
From GlobeNewswire News Releases
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
From PR Newswire
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
From GlobeNewswire News Releases
Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics
From GlobeNewswire News Releases
We Did The Math IBB Can Go To $150
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.